Taisho Pharmaceutical Holdings Stock

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, provides pharmaceutical and health-related products, as well as healthcare related information and services.

The company conducts business through the Self-Medication Operation Group (over-the-counter (OTC) drug and healthcare-related businesses) and the Prescription Pharmaceutical Operation Group (prescription pharmaceutical and related businesses)

Self-Medication Operation Group

The Self-Medication Operation Group in Japan develops products that meet the health-related needs of consumers, beginning with OTC drugs that could be purchased at drug stores and pharmacies, including health foods, skin care products and other health-related products. In OTC drugs, the company provides products in various categories that revolve around its mainstay brands, such as the Lipovitan series, which focuses on energy drinks, the Pabron series based around cold remedies, and the RiUP series of hair-growth medication and other hair-care products. In this group, the company is expanding into health-related products in addition to OTC drugs in line with changes in the health-related needs of consumers.

Prescription Pharmaceutical Operation Group

In the prescription pharmaceutical business, the company developed in-house and launched such products as the macrolide antibiotic Clarith, the type 2 diabetes mellitus agent Lusefi and the transdermal anti-inflammatory analgesic patch LOQOA as a company engaged in R&D.

With a focus on the domains of orthopedic disorders, metabolic diseases, infection diseases and central nervous system diseases, the company focuses to secure the early approval of compounds at the development stage and to reinforce its development pipeline by introducing entities/products in the late development stage from companies in Japan and internationally.

The company is also improving cooperation with external research institutes and companies to support the ongoing discovery of original substances through the incorporation of new technology and joint development initiatives.

Subsidiaries

In 2019, the company made Duoc Hau Giang Pharmaceutical DHG in Vietnam and UPSA in France consolidated subsidiaries, thereby establishing a business base in Europe in addition to Southeast Asia.

DHG

DHG is a major pharmaceutical company in Vietnam with its own nationwide distribution network. The company includes the three businesses of pharmaceuticals, nutritional foods and cosmetics. In particular, the pharmaceutical business, which handles generic drugs and OTC drugs. Further, antibiotics and antipyretic analgesics make up approximately 60% of sales. Dispatching personnel from the company and providing support for production enabled the company to acquire the PIC/S GMP and Japan GMP standards for DHG in preparation for the future export of pharmaceutical products.

UPSA

UPSA focuses on the OTC drug market. In addition, the company is expanding internationally with operations covering approximately 60 countries worldwide, including Europe (both Central and Eastern), Africa and Vietnam. UPSA handles the five product categories of antipyretic/analgesic, cough and cold, sleep aids, gastrointestinal, and vitamins. Approximately 80% of sales are accounted for by antipyretics/analgesics and cough and cold remedies.

History

Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912. The company was incorporated in 2011.